KLK3 and prostate cancer: Notably, this protocol achieved clinically significant prostate cancer (csPCa) detection in 9.2% of the cohort (21/229) with a 54.6% reduction in unnecessary biopsies through deferred management of PI-RADS 3 lesions, demonstrating the potential of bpMRI as a PSA-agnostic primary screening tool (26).